Novavax Inc. closed 68.94% below its 52-week high of $23.86, which the company achieved on June 6th.

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, ...

B. Riley decreased their FY2024 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley ...

Researchers at the Wuhan Institute of Virology in China said they discovered a new coronavirus in bats that enters cells ...

Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%. At ...

Bullish option flow detected in Novavax (NVAX) with 23,789 calls trading, 3x expected, and implied vol increasing over 8 points to 114.25%.

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by 12.64%. The Zacks Consensus ...

Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%.

Sangamo Therapeutics has higher earnings, but lower revenue than Novavax. Novavax is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more ...

Shares of Novavax Inc. NVAX slipped 1.25% to $7.92 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.47% to 19,962.